Details for New Drug Application (NDA): 211775
✉ Email this page to a colleague
NDA 211775 describes CEFIXIME, which is a drug marketed by Alkem Labs Ltd, Aurobindo Pharma Ltd, Belcher, and Chartwell Rx, and is included in six NDAs. It is available from five suppliers. Additional details are available on the CEFIXIME profile page.
The generic ingredient in CEFIXIME is cefixime. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefixime profile page.
The generic ingredient in CEFIXIME is cefixime. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Summary for 211775
| Tradename: | CEFIXIME |
| Applicant: | Alkem Labs Ltd |
| Ingredient: | cefixime |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 211775
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 100MG/5ML | ||||
| Approval Date: | Feb 19, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 200MG/5ML | ||||
| Approval Date: | Feb 19, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
